Over the forecast period, an increase in the number of drugs approved by the U.S. Food and Drug Administration (FDA) for the treatment of Cervical Cancer Drugs Market is anticipated to fuel market growth. For instance, the U.S. Food and Drug Administration (FDA) approved Mvasi (bevacizumab-awwb) as an Avastin (bevacizumab) biosimilar in September 2017 for the treatment of multiple cancers, including cervical, lung, brain, colorectal, and kidney cancer. Mvasi is prescribed for cervical cancer that has spread to other parts of the body. The U.S. FDA approved Genentech's Avastin, a bevacizumab solution for intravenous infusion used in conjunction with paclitaxel to treat metastatic, recurrent, or persistent cervical cancer, in August 2014.
Read More @ https://cmiinfonest.blogspot.com/2022/12/cervical-cancer-drugs-market-global.html
